{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:32:18Z","timestamp":1768433538103,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,9,6]],"date-time":"2016-09-06T00:00:00Z","timestamp":1473120000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10067-016-3398-3","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T22:34:09Z","timestamp":1473114849000},"page":"279-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Methotrexate intolerance in the treatment of rheumatoid arthritis (RA): effect of adding caffeine to the management regimen"],"prefix":"10.1007","volume":"36","author":[{"given":"Anand Narayan","family":"Malaviya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,6]]},"reference":[{"key":"3398_CR1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","volume":"57","author":"BN Cronstein","year":"2005","unstructured":"Cronstein BN (2005) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163\u2013172","journal-title":"Pharmacol Rev"},{"key":"3398_CR2","first-page":"16","volume":"124","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt ME (2013) Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc 124:16\u201325","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"3398_CR3","first-page":"473","volume":"58","author":"J \u015awierkot","year":"2006","unstructured":"\u015awierkot J, Szechi\u0144ski J (2006) Methotrexate in rheumatoid arthritis. Pharmacol Rep 58:473\u2013492","journal-title":"Pharmacol Rep"},{"key":"3398_CR4","first-page":"168","volume":"65","author":"H Tian","year":"2007","unstructured":"Tian H, Cronstein BN (2007) Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Joint Dis 65:168\u2013173","journal-title":"Bull NYU Hosp Joint Dis"},{"key":"3398_CR5","unstructured":"Bernstein S. 2014 ACR\/ARHP Annual Meeting: Weinblatt ME, Kremer J. Methotrexate Use in Patients with RA. The Rheumatologist - [Available from: http:\/\/www.the-rheumatologist.org\/article\/2014-acrarhp-annual-meeting-methotrexate-use-in-patients-with-ra\/ ]"},{"key":"3398_CR6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ncprheum0562","volume":"3","author":"J Dale","year":"2007","unstructured":"Dale J, Alcorn N, Capell H, Madhok R (2007) Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol 3:450\u2013458","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"Suppl 1","key":"3398_CR7","first-page":"S29","volume":"71","author":"EM Ruderman","year":"2013","unstructured":"Ruderman EM (2013) The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis. Bull Hosp Jt Dis 71(Suppl 1):S29\u2013S32","journal-title":"Bull Hosp Jt Dis"},{"issue":"Suppl 1","key":"3398_CR8","first-page":"S9","volume":"71","author":"T Pincus","year":"2013","unstructured":"Pincus T, Gibson KA, Castrejon I (2013) Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis 71(Suppl 1):S9\u201319","journal-title":"Bull Hosp Jt Dis"},{"key":"3398_CR9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762\u2013784","journal-title":"Arthritis Rheum"},{"key":"3398_CR10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625\u2013639","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3398_CR11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/ard.2005.049601","volume":"65","author":"BN Cronstein","year":"2006","unstructured":"Cronstein BN (2006) Going with the flow: methotrexate, adenosine, and blood flow. Ann Rheum Dis 65:421\u2013422","journal-title":"Ann Rheum Dis"},{"key":"3398_CR12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1152\/jappl.1994.76.1.5","volume":"76","author":"BN Cronstein","year":"1994","unstructured":"Cronstein BN (1994) Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 76:5\u201313","journal-title":"J Appl Physiol"},{"key":"3398_CR13","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1073\/pnas.88.6.2441","volume":"88","author":"BN Cronstein","year":"1991","unstructured":"Cronstein BN, Eberle MA, Gruber HE, Levin RI (1991) Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 88:2441\u20132445","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3398_CR14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","volume":"60","author":"M Cutolo","year":"2001","unstructured":"Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RV (2001) Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 60:729\u2013735","journal-title":"Ann Rheum Dis"},{"key":"3398_CR15","doi-asserted-by":"crossref","first-page":"e000287","DOI":"10.1136\/rmdopen-2016-000287","volume":"2","author":"JM Kremer","year":"2016","unstructured":"Kremer JM, Lawrence DA, Hamilton R, McInnes IB (2016) Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD Open 2:e000287","journal-title":"RMD Open"},{"key":"3398_CR16","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.39031","volume":"67","author":"AP Cribbs","year":"2015","unstructured":"Cribbs AP, Kennedy A, Penn H, Amjadi P, Green P, Read JE, et al. (2015) Methotrexate restores regulatory T cell function through Demethylation of the FoxP3 upstream enhancer in patients with rheumatoid arthritis. Arthritis Rheumatol 67:1182\u20131192","journal-title":"Arthritis Rheumatol"},{"key":"3398_CR17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrd3955","volume":"12","author":"JF Chen","year":"2013","unstructured":"Chen JF, Eltzschig HK, Fredholm BB (2013) Adenosine receptors as drug targets\u2014what are the challenges? Nat Rev Drug Discov 12:265\u2013286","journal-title":"Nat Rev Drug Discov"},{"key":"3398_CR18","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.2174\/092986711797535335","volume":"18","author":"S Paul","year":"2011","unstructured":"Paul S, Elsinga PH, Ishiwata K, Dierckx RA, van Waarde A, Adenosine A (2011) (1) receptors in the central nervous system: their functions in health and disease, and possible elucidation by PET imaging. Curr Med Chem 18:4820\u20134835","journal-title":"Curr Med Chem"},{"issue":"Suppl 1","key":"3398_CR19","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JAD-2010-1379","volume":"20","author":"JA Ribeiro","year":"2010","unstructured":"Ribeiro JA, Sebastiao AM (2010) Caffeine and adenosine. J Alzheimers Dis 20(Suppl 1):S3\u201315","journal-title":"J Alzheimers Dis"},{"key":"3398_CR20","doi-asserted-by":"crossref","first-page":"R217","DOI":"10.1186\/ar4413","volume":"15","author":"MB Calasan","year":"2013","unstructured":"Calasan MB, van den Bosch OF, Creemers MC, Custers M, Heurkens AH, van Woerkom JM, et al. (2013) Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther 15:R217","journal-title":"Arthritis Res Ther"},{"key":"3398_CR21","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/art.30367","volume":"63","author":"M Bulatovic","year":"2011","unstructured":"Bulatovic M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W, Hoppenreijs EP, et al. (2011) High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum 63:2007\u20132013","journal-title":"Arthritis Rheum"},{"key":"3398_CR22","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10067-016-3243-8","volume":"35","author":"N Fatimah","year":"2016","unstructured":"Fatimah N, Salim B, Nasim A, Hussain K, Gul H, Niazi S (2016) Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire. Clin Rheumatol 35:1341\u20131345","journal-title":"Clin Rheumatol"},{"key":"3398_CR23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0022-3565(25)20409-8","volume":"258","author":"I Biaggioni","year":"1991","unstructured":"Biaggioni I, Paul S, Puckett A, Arzubiaga C (1991) Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther 258:588\u2013593","journal-title":"J Pharmacol Exp Ther"},{"key":"3398_CR24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1756-185X.2010.01564.x","volume":"13","author":"AN Malaviya","year":"2010","unstructured":"Malaviya AN, Sharma A, Agarwal D, Kapoor S, Garg S, Sawhney S (2010) Low-dose and high-dose methotrexate are two different drugs in practical terms. Int J Rheum Dis 13:288\u2013293","journal-title":"Int J Rheum Dis"},{"key":"3398_CR25","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s10067-016-3283-0","volume":"35","author":"AN Malaviya","year":"2016","unstructured":"Malaviya AN, Gogia SB (2016) Treatment of rheumatoid arthritis (RA) in India\u2013how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal. Clin Rheumatol 35:2163\u201373","journal-title":"Clin Rheumatol"},{"key":"3398_CR26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/art.10766","volume":"48","author":"G Nesher","year":"2003","unstructured":"Nesher G, Mates M, Zevin S (2003) Effect of caffeine consumption on the efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 48:571\u2013572","journal-title":"Arthritis Rheum"},{"key":"3398_CR27","first-page":"1275","volume":"33","author":"E Benito-Garcia","year":"2006","unstructured":"Benito-Garcia E, Heller JE, Chibnik LB, Maher NE, Matthews HM, Bilics JA, et al. (2006) Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J Rheumatol 33:1275\u20131281","journal-title":"J Rheumatol"},{"key":"3398_CR28","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1002\/art.22129","volume":"54","author":"T Dervieux","year":"2006","unstructured":"Dervieux T, Greenstein N, Kremer J (2006) Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54:3095\u20133103","journal-title":"Arthritis Rheum"},{"key":"3398_CR29","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/art.21726","volume":"54","author":"JA Wessels","year":"2006","unstructured":"Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YPM, Allaart CF, et al. (2006) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54:1087\u20131095","journal-title":"Arthritis Rheum"},{"key":"3398_CR30","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2217\/pgs.15.145","volume":"16","author":"Y Ghodke-Puranik","year":"2015","unstructured":"Ghodke-Puranik Y, Puranik AS, Shintre P, Joshi K, Patwardhan B, Lamba J, et al. (2015) Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Pharmacogenomics 16:2019\u20132034","journal-title":"Pharmacogenomics"},{"key":"3398_CR31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3109\/s10165-012-0685-y","volume":"23","author":"E Dalkilic","year":"2013","unstructured":"Dalkilic E, Sahbazlar M, Gullulu M, Yavuz M, Dilek K, Ersoy A, et al. (2013) The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis. Mod Rheumatol 23:525\u2013528","journal-title":"Mod Rheumatol"},{"key":"3398_CR32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.7897\/2230-8407.050693","volume":"5","author":"M Kranthi-Kumar","year":"2014","unstructured":"Kranthi-Kumar M, Kiran-Kumar M (2014) The comparative data between various brands of tea powders and green tea. Int Jour Pharma Sci & Res 5:454\u2013459","journal-title":"Int Jour Pharma Sci & Res"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3398-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3398-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3398-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T16:54:59Z","timestamp":1749574499000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3398-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,6]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["3398"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3398-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,6]]}}}